Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China

Abstract On 10 January 2020, a new coronavirus causing a pneumonia outbreak in Wuhan City in central China was denoted as 2019-nCoV by the World Health Organization (WHO). As of 24 January 2020, there were 887 confirmed cases of 2019-nCoV infection, including 26 deaths, reported in China and other countries. Therefore, combating this new virus and stopping the epidemic is a matter of urgency. Here, we focus on advances in research and development of fast diagnosis methods, as well as potential prophylactics and therapeutics to prevent or treat 2019-nCoV infection.

[1]  Lu Lu,et al.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.

[2]  B. Schweighardt,et al.  The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy , 2019, Molecular therapy. Methods & clinical development.

[3]  Shibo Jiang,et al.  A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV , 2013, Virology Journal.

[4]  Sun-Woo Yoon,et al.  Simultaneous detection of severe acute respiratory syndrome, Middle East respiratory syndrome, and related bat coronaviruses by real-time reverse transcription PCR , 2017, Archives of Virology.

[5]  Shibo Jiang,et al.  Middle East respiratory syndrome: current status and future prospects for vaccine development , 2015, Expert opinion on biological therapy.

[6]  J. Mascola,et al.  A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial , 2008, Vaccine.

[7]  Shibo Jiang,et al.  Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein , 2006, The Journal of Immunology.

[8]  A. Debnath,et al.  The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 gp41 Is Critical for Viral Fusion and Entry , 2012, PloS one.

[9]  Elissa M. Hudspeth,et al.  Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate , 2014, Human vaccines & immunotherapeutics.

[10]  K. To,et al.  Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.

[11]  D. Aird,et al.  Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway , 2008, PLoS pathogens.

[12]  B. Murphy,et al.  Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jaap Goudsmit,et al.  Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants , 2005, Journal of Virology.

[14]  C. Peters,et al.  Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV , 2007, Vaccine.

[15]  Y. Choi,et al.  One-Pot Reverse Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) for Detecting MERS-CoV , 2017, Front. Microbiol..

[16]  B. Prabhakar,et al.  Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential , 2011, Reviews in medical virology.

[17]  D. Weiner,et al.  Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial , 2019, The Lancet Infectious Diseases.

[18]  Jingwei Huang,et al.  Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain , 2019, Viruses.

[19]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[20]  Shibo Jiang,et al.  Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC , 2013, Journal of Infection.

[21]  Michelle L. Bryson,et al.  Oral Ribavirin for the Treatment of Noninfluenza Respiratory Viral Infections , 2015, The Annals of pharmacotherapy.

[22]  L. Saif,et al.  Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity. , 1993, The Journal of general virology.

[23]  R. Baric,et al.  Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.

[24]  Leshan Xiu,et al.  Establishment and Application of a Universal Coronavirus Screening Method Using MALDI-TOF Mass Spectrometry , 2017, Front. Microbiol..

[25]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[26]  Xiaoyan Lu,et al.  Real-Time Reverse Transcription-PCR Assay Panel for Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Clinical Microbiology.

[27]  Shibo Jiang,et al.  Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses , 2017, Science China Life Sciences.

[28]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[29]  G. Sutter,et al.  Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein , 2015, Journal of Virology.

[30]  Nam-Hyuk Cho,et al.  Evaluation and Clinical Validation of Two Field–Deployable Reverse Transcription-Insulated Isothermal PCR Assays for the Detection of the Middle East Respiratory Syndrome–Coronavirus , 2017, The Journal of Molecular Diagnostics.

[31]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[32]  Z. Memish,et al.  Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study , 2014, The Lancet Infectious Diseases.

[33]  Jincun Zhao,et al.  A Rapid and Specific Assay for the Detection of MERS-CoV , 2018, Front. Microbiol..

[34]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[35]  O. Chailapakul,et al.  Multiplex Paper-Based Colorimetric DNA Sensor Using Pyrrolidinyl Peptide Nucleic Acid-Induced AgNPs Aggregation for Detecting MERS-CoV, MTB, and HPV Oligonucleotides , 2017, Analytical chemistry.

[36]  Linqi Zhang,et al.  Antibodies and vaccines against Middle East respiratory syndrome coronavirus , 2019, Emerging microbes & infections.

[37]  Yi Shi,et al.  Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains , 2017, Nature Communications.

[38]  G. Yancopoulos,et al.  Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection , 2015, Proceedings of the National Academy of Sciences.

[39]  S. Perlman,et al.  Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.

[40]  Tsugunori Notomi,et al.  Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP) , 2014, Virology Journal.

[41]  D. Barnard,et al.  Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV , 2011, Vaccine.

[42]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[43]  Shibo Jiang,et al.  Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies , 2005, The Journal of Immunology.

[44]  Baoan Yang,et al.  Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines , 2005, Virology.

[45]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[46]  P. Patel,et al.  Reverse Transcription Recombinase Polymerase Amplification Assay for the Detection of Middle East Respiratory Syndrome Coronavirus , 2013, PLoS currents.

[47]  B. Bosch,et al.  Specific serology for emerging human coronaviruses by protein microarray. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[48]  Lu Lu,et al.  A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike , 2019, Science Advances.

[49]  Z. Memish,et al.  Investigation of Anti–Middle East Respiratory Syndrome Antibodies in Blood Donors and Slaughterhouse Workers in Jeddah and Makkah, Saudi Arabia, Fall 2012 , 2013, The Journal of infectious diseases.

[50]  Robert J. Fischer,et al.  Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape , 2018, Journal of Virology.

[51]  G. Gao,et al.  T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV , 2016, Antiviral Research.

[52]  Jianmin Wang,et al.  Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset , 2017, The Journal of infectious diseases.

[53]  Robert J. Fischer,et al.  Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model , 2017, npj Vaccines.

[54]  Shibo Jiang,et al.  Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry , 2004, Biochemical and Biophysical Research Communications.

[55]  M. Izadi,et al.  Development of Dual TaqMan Based One-Step rRT-PCR Assay Panel for Rapid and Accurate Diagnostic Test of MERS-CoV: A Novel Human Coronavirus, Ahead of Hajj Pilgrimage , 2016, Iranian Red Crescent medical journal.

[56]  G. Olinger,et al.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies , 2017, Drugs.

[57]  Krishna Shankara Narayanan,et al.  Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus , 2016, Human vaccines & immunotherapeutics.

[58]  Jincun Zhao,et al.  DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice , 2017, Vaccine.

[59]  T. Bestebroer,et al.  Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[60]  P. Millett,et al.  The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts , 2018, Antiviral Research.

[61]  Ji Yeun Kim,et al.  Arch-shaped multiple-target sensing for rapid diagnosis and identification of emerging infectious pathogens , 2018, Biosensors and Bioelectronics.

[62]  Andrew Rambaut,et al.  Pacing a small cage: mutation and RNA viruses , 2008, Trends in Ecology & Evolution.

[63]  C. Olsen.  A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination , 1993, Veterinary Microbiology.

[64]  R. Baric,et al.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution , 2014, Proceedings of the National Academy of Sciences.

[65]  F. Sciacca,et al.  DNA , 2020, Radiopaedia.org.

[66]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[67]  Zhènglì Shí,et al.  An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies , 2020, Emerging microbes & infections.

[68]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[69]  Shibo Jiang,et al.  Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.

[70]  Herman Tse,et al.  Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests , 2013, Journal of Infection.

[71]  Hongzhou Lu,et al.  Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle , 2020, Journal of medical virology.

[72]  Yufei Wang,et al.  Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection , 2016, Antiviral Research.